Share Name Share Symbol Market Type Share ISIN Share Description
Summit Corporation LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 169.00p 165.00p 173.00p 169.00p 169.00p 169.00p 277.00 07:32:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.4 -20.1 -28.8 - 103.91

Summit Corp Share Discussion Threads

Showing 37951 to 37975 of 37975 messages
Chat Pages: 1519  1518  1517  1516  1515  1514  1513  1512  1511  1510  1509  1508  Older
DateSubjectAuthorDiscuss
02/12/2016
19:14
Depositary Fees Notification Summit Therapeutics CUSIP: 86627R102 Bank of New York Mellon Http://www.dtcc.com/legal/important-notices
football
02/12/2016
13:56
Agree completely Luminoso. Winning the award for "Clinical Advance Of The Year" will surely have been a been an opportunity to talk the talk with the movers and shakers, under far more enlightening circumstances than any invitation to present in a board room? I do hope they took advantage of the occasion.
hugus maximus
02/12/2016
11:23
Just US traders taking this down to another bottom, so they can pile back in before C Diff news hits. I hope to join them at the bottom and add more, just not sure where it will be. I have freed up funds from elsewhere as a really cheap buying opp seems likely.
luminoso
02/12/2016
09:50
sorrento06 i agree,it is disgraceful that we get no information at all.there must be something that they can tell us to cheer us up,gl,joe.
joe shone
02/12/2016
07:27
I genuinely can't believe we haven't had an RNSon this share. With all the things going on, delayed CDiff, awards...
sorrento06
01/12/2016
10:22
IMO that win deserves a 1200 RNS.
kmjs
01/12/2016
10:12
Used to run some awards (in a different industry) and they were great fun and made a real difference (for a short time at least) to the winning teams. See the US bill looks to be sailing through. We might just get to enjoy the fruits of the rare disease voucher! htTps://endpts.com/21st-centure-cures-act-supporters-crush-meager-house-opposition-heads-to-a-final-showdown-in-the-senate/
waterloo01
01/12/2016
09:08
However ... life is cruel and I've found that winning awards in the UK can be bad news for the long term career. (11k shares sold first thing) Here's to a long and fruitful career for both the C Diff drug and Summit! (Noises off - the sound of shares selling like hot cakes.)
hugus maximus
30/11/2016
23:03
Well done all at Summit!
hyper al
30/11/2016
22:54
Great stuff guys and gals ... CONGRATULATIONS SUMMIT ... and typically modest, they haven't even announced it on their Twitter feed (or perhaps too busy celebrating?!) Wonderful ... hope all are enjoying a moment of glory.
hugus maximus
30/11/2016
22:38
Excellent news, well done Summit !!
jag63
30/11/2016
22:14
They won !!!!! Scrip ‏@PharmaScrip 51s52 seconds ago .@Summitplc’s Phase II CoDIFy study win #ScripAwards 2016 QuintilesIMS' Clinical Advance of the Year Award 0 replies 0 retweets 0 likes Reply Retweet Like More
chrisatrdg
30/11/2016
21:14
Summit Therapeutics ‏@Summitplc 6m6 minutes ago We've updated https://clinicaltrials.gov/ct2/show/NCT02858362 … w/ additional locations & contact info for PhaseOut DMD #utrophin #Duchenne
someuwin
30/11/2016
20:21
Summit Therapeutics ‏@Summitplc 32m32 minutes ago Our team is @PharmaScrip 's #ScripAwards tonight. We're shortlisted for clinical advance of the year for the Ph 2 of ridinilazole in #cdiff
someuwin
29/11/2016
18:37
htTps://endpts.com/house-lines-up-biotech-lollipops-as-support-grows-for-an-epic-21st-century-cures-act/ A number of measures in here that should be good for SUMM, including continuing with the voucher programme (ie the one we got), biomarkers and generally speeding up FDA, including specific mention of anti-biotics Edit: the voucher only gets awarded if we get approvals, but has a value in itself with a number having sold for $350m a pop
waterloo01
29/11/2016
07:37
freemoney, whoever edited the page has taken the Wainwright note as it's base. Actually it's a straight lift.
waterloo01
29/11/2016
07:30
I've noticed the Ridinilazole Wikipedia page recently. The commercialisation section seems to imply the deal has already been done. But obviously we would have been told officially if it had. Remember anyone can edit these pages. Either way it makes interesting reading for now and I'll be interested to see how far the official deal and numbers will differ.... hopefully we'll know shortly... GLA https://en.wikipedia.org/wiki/Ridinilazole Commercialization "Ridinilazole is manufactured by Summit Therapeutics. Summit Therapeutics plans to partner with another pharmaceutical company to begin Phase 3 trials. They predict for both the US and EU launch to occur in 2021 with peak sales of £930 million. Summit will receive a flat 20% royalty rate. Models predict that royalties will rise from £25.6 million in FY2022 to £75.2 in FY2027. Ridinilazole has been de-risked with positive Phase 2 data.[4] Summit estimates that the price will be $1,200 for one course of therapy in the US and approximately 20% less in the EU. This is in contrast to Merck's Dificid (fidaxomicin) which was priced at $2,800 per course of therapy. Dificid did not sell well because it cost nearly four times as much as the generic vancomycin alternatives.[4] According to H.C. Wainwright, ridinilazole is currently undervalued since ridinilazole allows the patients gut microflora to be preserved which helps prevents deadly recurrent infections and allows for the use of ridinilazole as a first line therapy, in contrast with antibiotics already on the market.
freemoney1
28/11/2016
20:08
Not seen any notice of a webcast? hTtp://community.parentprojectmd.org/profiles/blogs/action-alert-tell-congress-to-pass-21st-century-cures Is this similar/same as Trumps idea? Could prove rather useful!
waterloo01
28/11/2016
18:20
NASDAQ still maintaining momentum - fingers crossed.Looking forward to Tuesday's webcast by Summit (hopefully if same as last year) at: OPPENHEIMER & COMPANY LIFE SCIENCES SUMMIT 29 November 2016, New York City, US Edit: Notice of webcast not yet notified but expecting RNS Tuesday (i.e. expecting per last year).
chrisatrdg
28/11/2016
17:55
It's surely time for an update on RDZ. Will it mirror the SRPT deal? And who knows about the shelf zombies? I noted recently the BMS were more active (not directly relevant) hTtps://endpts.com/bristol-myers-hands-over-100m-in-cash-for-a-new-fibrosis-drug-beefing-up-nash-focus/
waterloo01
28/11/2016
17:17
liking the action on nasdaq.....
luminoso
27/11/2016
19:00
Amyloid hypothesis loosing traction in Alzheimer's. Focus back on Tau Interesting .... Summit
freedosh
25/11/2016
07:48
Morning Sorrento ... it's "the day after thanksgiving" and a Public Holiday in the USA, so highly unlikely. But there must be news soon. Meanwhile a huge opportunity to buy shares at a ridiculous Black Friday discount!
hugus maximus
25/11/2016
00:50
Is today the day for C diff?
sorrento06
24/11/2016
18:04
Chris, they could have been buys at yesterdays trading range.... and I suspect they were since the price moved up. Buy 'em cheap while you still can :-)
freemoney1
Chat Pages: 1519  1518  1517  1516  1515  1514  1513  1512  1511  1510  1509  1508  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20161205 08:39:20